<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000568.v1.p1" parentStudy="phs000568.v1.p1" createDate="2012-12-04" modDate="2012-12-04">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Matthew Meyerson, MD, PhD</td><td>Dana Farber Cancer Institute, Boston MA</td></tr>
		<tr><td>Principal Investigator</td><td>Todd Golub, MD</td><td>Broad Institute, Cambridge MA</td></tr>
		<tr><td>Funding Source</td><td>Slim Initiative for Genomic Medicine in the Americas (SIGMA)</td><td>Carlos Slim Foundation</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Sequencing of Solitary Fibrous Tumors</StudyNameEntrez>
	<StudyNameReportPage>Genomic Sequencing of Solitary Fibrous Tumors</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Solitary fibrous tumors (SFTs) are rare mesenchymal tumors that can be benign or malignant. In this study, we sequenced and analyzed the exomes of 17 SFT matched tumor and normal pairs. This study appertains to a large endeavor to characterize cancers as part of the Slim Initiative for Genomic Medicine in the Americas (SIGMA) project.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Participants were eligible for inclusion in this study only if their SFT was treatment naive.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="20566782"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20209623"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20527023"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Solitary Fibrous Tumors"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Matthew Meyerson, MD, PhD</AttName>
			<Institution>Dana Farber Cancer Institute, Boston MA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Todd Golub, MD</AttName>
			<Institution>Broad Institute, Cambridge MA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Slim Initiative for Genomic Medicine in the Americas (SIGMA)</AttName>
			<Institution>Carlos Slim Foundation</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000568.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000568.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000568.v1.p1" FileName="eNCI_0152_DUC_11.27.2012.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the standard Data Use Certification. The data will only be used for research purposes. Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
